Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy

Hendrée E. Jones, Erin Dengler, Anna Garrison, Kevin E. O'Grady, Carl Seashore, Evette Horton, Kim Andringa, Lauren M Jansson, John Thorp

Research output: Contribution to journalArticle

Abstract

Background: Buprenorphine pharmacotherapy for opioid-dependent pregnant women is associated with maternal and neonatal outcomes superior to untreated opioid dependence. However, the literature is inconsistent regarding the possible existence of a dose-response relationship between maternal buprenorphine dose and neonatal clinical outcomes. Methods: The present secondary analysis study (1) examined the relationship between maternal buprenorphine dose at delivery and neonatal abstinence syndrome (NAS) peak score, estimated gestational age at delivery, Apgar scores at 1 and 5. min, neonatal head circumference, length, and weight at birth, amount of morphine needed to treat NAS, duration of NAS treatment, and duration of neonatal hospital stay and (2) compared neonates who required pharmacotherapy for NAS to neonates who did not require such pharmacotherapy on these same outcomes, in 58 opioid-dependent pregnant women receiving buprenorphine as participants in a randomized clinical trial. Results: (1) Analyses failed to provide evidence of a relationship between maternal buprenorphine dose at delivery and any of the 10 outcomes (all p-values. >. .48) and (2) significant mean differences between the untreated (n= 31) and treated (n= 27) for NAS groups were found for duration of neonatal hospital stay and NAS peak score (both p-values. <.001). Conclusions: (1) Findings failed to support the existence of a dose-response relationship between maternal buprenorphine dose at delivery and any of 10 neonatal clinical outcomes, including NAS severity and (2) that infants treated for NAS had a higher mean NAS peak score and, spent a longer time in the hospital than did the group not treated for NAS is unsurprising.

Original languageEnglish (US)
Pages (from-to)414-417
Number of pages4
JournalDrug and Alcohol Dependence
Volume134
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Neonatal Abstinence Syndrome
Buprenorphine
Mothers
Drug therapy
Pregnancy
Opioid Analgesics
Drug Therapy
Pregnant Women
Length of Stay
Morphine
Newborn Infant
Apgar Score
Birth Weight
Gestational Age

Keywords

  • Buprenorphine
  • Neonatal abstinence syndrome
  • Neonate
  • Opioid use disorder
  • Pregnancy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Jones, H. E., Dengler, E., Garrison, A., O'Grady, K. E., Seashore, C., Horton, E., ... Thorp, J. (2014). Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence, 134(1), 414-417. https://doi.org/10.1016/j.drugalcdep.2013.11.006

Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. / Jones, Hendrée E.; Dengler, Erin; Garrison, Anna; O'Grady, Kevin E.; Seashore, Carl; Horton, Evette; Andringa, Kim; Jansson, Lauren M; Thorp, John.

In: Drug and Alcohol Dependence, Vol. 134, No. 1, 01.01.2014, p. 414-417.

Research output: Contribution to journalArticle

Jones, HE, Dengler, E, Garrison, A, O'Grady, KE, Seashore, C, Horton, E, Andringa, K, Jansson, LM & Thorp, J 2014, 'Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy', Drug and Alcohol Dependence, vol. 134, no. 1, pp. 414-417. https://doi.org/10.1016/j.drugalcdep.2013.11.006
Jones, Hendrée E. ; Dengler, Erin ; Garrison, Anna ; O'Grady, Kevin E. ; Seashore, Carl ; Horton, Evette ; Andringa, Kim ; Jansson, Lauren M ; Thorp, John. / Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. In: Drug and Alcohol Dependence. 2014 ; Vol. 134, No. 1. pp. 414-417.
@article{fdddfe1eadb44234bfc5c1ff4e6d1f8c,
title = "Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy",
abstract = "Background: Buprenorphine pharmacotherapy for opioid-dependent pregnant women is associated with maternal and neonatal outcomes superior to untreated opioid dependence. However, the literature is inconsistent regarding the possible existence of a dose-response relationship between maternal buprenorphine dose and neonatal clinical outcomes. Methods: The present secondary analysis study (1) examined the relationship between maternal buprenorphine dose at delivery and neonatal abstinence syndrome (NAS) peak score, estimated gestational age at delivery, Apgar scores at 1 and 5. min, neonatal head circumference, length, and weight at birth, amount of morphine needed to treat NAS, duration of NAS treatment, and duration of neonatal hospital stay and (2) compared neonates who required pharmacotherapy for NAS to neonates who did not require such pharmacotherapy on these same outcomes, in 58 opioid-dependent pregnant women receiving buprenorphine as participants in a randomized clinical trial. Results: (1) Analyses failed to provide evidence of a relationship between maternal buprenorphine dose at delivery and any of the 10 outcomes (all p-values. >. .48) and (2) significant mean differences between the untreated (n= 31) and treated (n= 27) for NAS groups were found for duration of neonatal hospital stay and NAS peak score (both p-values. <.001). Conclusions: (1) Findings failed to support the existence of a dose-response relationship between maternal buprenorphine dose at delivery and any of 10 neonatal clinical outcomes, including NAS severity and (2) that infants treated for NAS had a higher mean NAS peak score and, spent a longer time in the hospital than did the group not treated for NAS is unsurprising.",
keywords = "Buprenorphine, Neonatal abstinence syndrome, Neonate, Opioid use disorder, Pregnancy",
author = "Jones, {Hendr{\'e}e E.} and Erin Dengler and Anna Garrison and O'Grady, {Kevin E.} and Carl Seashore and Evette Horton and Kim Andringa and Jansson, {Lauren M} and John Thorp",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.drugalcdep.2013.11.006",
language = "English (US)",
volume = "134",
pages = "414--417",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy

AU - Jones, Hendrée E.

AU - Dengler, Erin

AU - Garrison, Anna

AU - O'Grady, Kevin E.

AU - Seashore, Carl

AU - Horton, Evette

AU - Andringa, Kim

AU - Jansson, Lauren M

AU - Thorp, John

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Buprenorphine pharmacotherapy for opioid-dependent pregnant women is associated with maternal and neonatal outcomes superior to untreated opioid dependence. However, the literature is inconsistent regarding the possible existence of a dose-response relationship between maternal buprenorphine dose and neonatal clinical outcomes. Methods: The present secondary analysis study (1) examined the relationship between maternal buprenorphine dose at delivery and neonatal abstinence syndrome (NAS) peak score, estimated gestational age at delivery, Apgar scores at 1 and 5. min, neonatal head circumference, length, and weight at birth, amount of morphine needed to treat NAS, duration of NAS treatment, and duration of neonatal hospital stay and (2) compared neonates who required pharmacotherapy for NAS to neonates who did not require such pharmacotherapy on these same outcomes, in 58 opioid-dependent pregnant women receiving buprenorphine as participants in a randomized clinical trial. Results: (1) Analyses failed to provide evidence of a relationship between maternal buprenorphine dose at delivery and any of the 10 outcomes (all p-values. >. .48) and (2) significant mean differences between the untreated (n= 31) and treated (n= 27) for NAS groups were found for duration of neonatal hospital stay and NAS peak score (both p-values. <.001). Conclusions: (1) Findings failed to support the existence of a dose-response relationship between maternal buprenorphine dose at delivery and any of 10 neonatal clinical outcomes, including NAS severity and (2) that infants treated for NAS had a higher mean NAS peak score and, spent a longer time in the hospital than did the group not treated for NAS is unsurprising.

AB - Background: Buprenorphine pharmacotherapy for opioid-dependent pregnant women is associated with maternal and neonatal outcomes superior to untreated opioid dependence. However, the literature is inconsistent regarding the possible existence of a dose-response relationship between maternal buprenorphine dose and neonatal clinical outcomes. Methods: The present secondary analysis study (1) examined the relationship between maternal buprenorphine dose at delivery and neonatal abstinence syndrome (NAS) peak score, estimated gestational age at delivery, Apgar scores at 1 and 5. min, neonatal head circumference, length, and weight at birth, amount of morphine needed to treat NAS, duration of NAS treatment, and duration of neonatal hospital stay and (2) compared neonates who required pharmacotherapy for NAS to neonates who did not require such pharmacotherapy on these same outcomes, in 58 opioid-dependent pregnant women receiving buprenorphine as participants in a randomized clinical trial. Results: (1) Analyses failed to provide evidence of a relationship between maternal buprenorphine dose at delivery and any of the 10 outcomes (all p-values. >. .48) and (2) significant mean differences between the untreated (n= 31) and treated (n= 27) for NAS groups were found for duration of neonatal hospital stay and NAS peak score (both p-values. <.001). Conclusions: (1) Findings failed to support the existence of a dose-response relationship between maternal buprenorphine dose at delivery and any of 10 neonatal clinical outcomes, including NAS severity and (2) that infants treated for NAS had a higher mean NAS peak score and, spent a longer time in the hospital than did the group not treated for NAS is unsurprising.

KW - Buprenorphine

KW - Neonatal abstinence syndrome

KW - Neonate

KW - Opioid use disorder

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84890239286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890239286&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2013.11.006

DO - 10.1016/j.drugalcdep.2013.11.006

M3 - Article

C2 - 24290979

AN - SCOPUS:84890239286

VL - 134

SP - 414

EP - 417

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1

ER -